Search clinical trials for: non-Fc FVIII replacement products

Total 507 results

Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Skane University Hospital
CSL Behring; Versiti

Completed

The Von Willebrand Disease (VWD) International Prophylaxis Study (VIP)

Von Willebrand Disease

United States, Sweden
Emory University
Bioverativ Therapeutics Inc.

Completed

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

Hemophilia | Menstrual Flow Excessive

United States
Children's Hospital Srebrnjak
Belupo; Podravka d.d.

Recruiting

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet in Obese Participants With Asthma

Obesity | Overweight | Asthma

Croatia
Children's Hospital Srebrnjak
Belupo; Podravka d.d.

Recruiting

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet

Body Weight | Overweight and Obesity

Croatia
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Hoffmann-La Roche

Completed

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Hemophilia A

United States, Korea, Republic of, Italy, South Africa, Spain, China, Japan, Poland, Australia, Costa Rica, Germany, Taiwan
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bayer
American Thrombosis and Hemostasis Network

Terminated

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Hemophilia A

United States
Coloplast A/S

Completed

Investigation of a New Stoma Product for People With a Stoma (CP288)

Peristomal Skin Complication

Norway
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Massachusetts General Hospital

Recruiting

Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population (MINT)

Obesity | Overweight | PreDiabetes | Diabetes Type 2

United States
Spark Therapeutics

Completed

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Blood Coagulation Disorder | Factor VIII Deficiency

United States, Australia, Thailand, Canada
Pfizer

Active, not recruiting

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Hemophilia A | Hemophilia B

United States, Canada, Spain, Australia, Korea, Republic of, Taiwan, Brazil, Italy, Japan, Turkey, Germany, United Kingdom, Saudi Arabia, France, Sweden, Belgium, Greece, Israel
Lund University

Withdrawn

Key Aspects of Medical Practice in Patients With Haemophilia A (KAPPA)

Joint Disease
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Medtronic Cardiac Surgery

Recruiting

Medtronic Cardiac Surgery PMCF Registry

Valve Disease, Heart

United States, Belgium, Greece, Germany, Netherlands, Austria, France, Italy, Switzerland, Spain
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
American Thrombosis and Hemostasis Network
Bayer; Shire; CSL Behring; Bioverativ Therapeutics Inc.

Completed

ATHN 2: Factor Switching Study

Hemophilia

United States
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Beth Israel Deaconess Medical Center

Completed

Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss

Obesity | Weight Loss

United States
Bayer

Completed

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (Leopold II)

Hemophilia A

China, United States, Ukraine, Taiwan, Mexico, Thailand, Romania, Colombia, Turkey, Serbia, Russian Federation, South Africa, Japan, Indonesia, Argentina, Czech Republic, India, Slovakia
Takeda

Not yet recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD)

Von Willebrand Disease (VWD)
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease

United States, Belgium, Spain, Italy, Turkey, Germany, Austria, France, Czechia, Russian Federation, Ukraine, United Kingdom, Netherlands
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
Capital Health, Canada
Sunnybrook Health Sciences Centre; Erasmus Medical Center; IWK Health Centre; Afexa... and other collaborators

Completed

Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors

Respiratory Tract Infection

Canada, Netherlands
Takeda
Baxalta Innovations GmbH, now part of Shire

Completed

rVWF IN PROPHYLAXIS

Von Willebrand Disease

United States, Spain, Italy, Turkey, Germany, Russian Federation, Netherlands, France, Canada
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Jiangsu Gensciences lnc.

Not yet recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Severe Hemophilia A

China
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
The League of Clinical Research, Russia

Completed

Health Related Quality of Life of Youth and Young Adults With Haemophilia A (RELOQ)

Hemophilia A

Russian Federation
University Hospital Southampton NHS Foundation...
Medical Research Council; University of Southampton

Completed

Women's Responses to Adjusted Product Placement and Its Effects on Diet - 1 (WRAPPED1) (WRAPPED1)

Diet Modification
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Indiana University
State University of New York at Buffalo

Completed

Renal Considerations in the Heat Stress Recommendations (Aim2)

Hyperthermia | Kidney Injury | Dehydration | Kidney Dysfunction | Hot Weather; Adverse Effect

United States
Rennes University Hospital

Terminated

Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury (EPURE)

Kidney Failure, Acute

France, Canada, Réunion
British American Tobacco (Investments) Limited
Celerion

Active, not recruiting

BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects

Smoking | Tobacco Use | Tobacco Smoking

United States
University of Reading

Completed

The Impact of Reformulated Foods on Cardiovascular Risk Factors (REFORM)

Obesity | Cardiovascular Disease | Type 2 Diabetes Mellitus

United Kingdom
Danone Research

Completed

Effect Of The Consumption Of Fermented Dairy Drink On Common Infections In Shift-Workers

Healthy

Belgium, France, Spain, United Kingdom
Sun Yat-sen University

Recruiting

The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study

Thalassemia Major | Transfusion-dependent Anemia

China
Wake Forest University Health Sciences

Completed

Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat (SILVER)

Abdominal Obesity

United States

Search clinical trials for: non-Fc FVIII replacement products

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations